Amneal Pharmaceuticals Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Amneal Pharmaceuticals stock.
View analyst ratings for Amneal Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Amneal Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amneal Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Amneal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, November 5th 2021.
View our earnings forecast for Amneal Pharmaceuticals.

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) released its earnings results on Sunday, August, 8th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.07. The business earned $535.10 million during the quarter, compared to analysts' expectations of $523.26 million. Amneal Pharmaceuticals had a net margin of 0.45% and a trailing twelve-month return on equity of 58.68%. The business's quarterly revenue was up 15.1% on a year-over-year basis. During the same period last year, the business posted $0.13 EPS.
View Amneal Pharmaceuticals' earnings history.

Amneal Pharmaceuticals' stock was trading at $3.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMRX shares have increased by 52.3% and is now trading at $4.95.
View which stocks have been most impacted by COVID-19.

Amneal Pharmaceuticals issued an update on its FY 2021 earnings guidance on Monday, September, 6th. The company provided earnings per share guidance of $0.700-$0.850 for the period, compared to the Thomson Reuters consensus estimate of $0.820. The company issued revenue guidance of $2.10 billion-$2.20 billion, compared to the consensus revenue estimate of $2.12 billion.

5 analysts have issued 1 year price objectives for Amneal Pharmaceuticals' stock. Their forecasts range from $5.50 to $9.00. On average, they expect Amneal Pharmaceuticals' stock price to reach $7.40 in the next year. This suggests a possible upside of 49.5% from the stock's current price.
View analysts' price targets for Amneal Pharmaceuticals or view top-rated stocks among Wall Street analysts.

23 employees have rated Amneal Pharmaceuticals CEO Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among Amneal Pharmaceuticals' employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Amneal Pharmaceuticals include Perrigo (PRGO), Allakos (ALLK), I-Mab (IMAB), Cerevel Therapeutics (CERE), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Arvinas (ARVN), TG Therapeutics (TGTX), Schrödinger (SDGR), Hypera (HYPMY), Turning Point Therapeutics (TPTX), Reata Pharmaceuticals (RETA), Arena Pharmaceuticals (ARNA), Galapagos (GLPG) and 23andMe (ME).
View all of AMRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Amneal Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.82%), BlackRock Inc. (2.36%), Neuberger Berman Group LLC (1.12%), State Street Corp (0.91%), Nuveen Asset Management LLC (0.74%) and Victory Capital Management Inc. (0.64%). Company insiders that own Amneal Pharmaceuticals stock include Chintu Patel, Chirag K Patel, Gautam Patel, Jeffrey P George, John Kiely, Joseph Todisco and Paul M Meister.
View institutional ownership trends for Amneal Pharmaceuticals.

AMRX stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Marshall Wace LLP, Marshall Wace LLP, BlackRock Inc., Cubist Systematic Strategies LLC, Prudential Financial Inc., Parametric Portfolio Associates LLC, and Group One Trading L.P..
View insider buying and selling activity for Amneal Pharmaceuticals or view top insider-selling stocks.

AMRX stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Dimensional Fund Advisors LP, Globeflex Capital L P, Vanguard Group Inc., State Street Corp, LSV Asset Management, Goldman Sachs Group Inc., and Charles Schwab Investment Management Inc.. Company insiders that have bought Amneal Pharmaceuticals stock in the last two years include Chintu Patel, Chirag K Patel, Gautam Patel, Jeffrey P George, John Kiely, Joseph Todisco, and Paul M Meister.
View insider buying and selling activity for Amneal Pharmaceuticals or or view top insider-buying stocks.

Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMRX stock can currently be purchased for approximately $4.95.

Amneal Pharmaceuticals has a market capitalization of $1.49 billion and generates $1.99 billion in revenue each year. The company earns $91.06 million in net income (profit) each year or $0.52 on an earnings per share basis.

Amneal Pharmaceuticals employs 6,000 workers across the globe.

The official website for Amneal Pharmaceuticals is www.amneal.com.

Amneal Pharmaceuticals is headquartered at 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807.

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at (908) 947-3120 or via email at [email protected].